Paper Details

  1. Home
  2. Paper Details

Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis.

Author: AlvarezBeatriz, CabelloAlfonso, González-CordónAna, GorgolasMiguel, Laguno CentenoMontserrat, MallolasJosep, Martínez-RebollarMaria, PrietoLaura, TorresBerta, de LazzariElisa, de la MoraLorena

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study highlights the growing prevalence of acute hepatitis C virus (AHC) infection among HIV+ men who have sex with men (MSM). Prior to the advent of effective Direct-Acting-Antivirals (DAAs), the recommended treatment for AHC was pegylated-interferon plus ribavirin, which was often rejected due to its side effects. This study underscores the importance of accessible and effective treatment options for AHC in this population.
Paper Details　
Original Abstract of the Article :
Acute hepatitis C virus (AHC) infection is increasingly common among HIV+ men who have sex with men (MSM). Until 2017, the guidelines recommended therapy with pegylated-interferon plus ribavirin with a mild sustained virological response (SVR). This prompted many patients to reject that treatment, a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.gastrohep.2020.06.019

データ提供：米国国立医学図書館（NLM）

A New Treatment for Hepatitis C in HIV-Positive Individuals

Hepatitis C virus (HCV) infection, a serious liver disease, poses a significant challenge for individuals with HIV. Imagine two desert travelers facing a dual threat, battling both a scorching sun and a hidden predator. This study explores the efficacy of a new combination therapy, elbasvir/grazoprevir, for treating early chronic HCV infection in HIV-positive individuals with mild fibrosis.

A Promising Treatment for HCV in HIV-Positive Individuals

The study found that elbasvir/grazoprevir was highly effective in clearing the HCV infection in HIV-positive patients. It’s like discovering a hidden oasis, offering a safe haven and a path to recovery. This treatment regimen has the potential to significantly improve the lives of those co-infected with HIV and HCV, reducing the risk of liver damage and complications.

A New Era of HCV Treatment

This study represents a significant advancement in the treatment of HCV infection in HIV-positive individuals. It’s a reminder that the desert of medical research is constantly yielding new breakthroughs, offering hope for those battling complex and challenging conditions.

Dr.Camel's Conclusion

This study highlights the remarkable progress made in the treatment of HCV, offering a new era of hope for individuals living with HIV and HCV co-infection. It's a reminder that even in the most challenging deserts of disease, there is always a path to recovery.

Date :
  1. Date Completed 2021-11-04
  2. Date Revised 2021-11-04
Further Info :

Pubmed ID

33041087

DOI: Digital Object Identifier

10.1016/j.gastrohep.2020.06.019

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.